Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Therapy continues as long as positive changes occur and is adjusted or discontinued if plateaus develop or goals are achieved
Understanding your oxidative stress profile and genetic predispositions can help guide whether these compounds merit consideration
Structure-based classification predicts drug response in EGFR-mutant NSCLC
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Franco, J
US$ 20.62
US$ 22.18
US$ 25.57
US$ 27.19
US$ 27.58
